What technology area does this patent fall under?

Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.

When was this patent published?

Publication date Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Patent metadata
Field	Value
Publication number	US-11453655-B2
Application number	US-202016994875-A
Country	US
Kind code	B2
Filing date	Aug 17, 2020
Priority date	Dec 9, 2016
Publication date	Sep 27, 2022
Grant date	Sep 27, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds of Formula (I):pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

First claim

Opening claim text (preview).

The invention claimed is: 1. Crystalline Form A of Compound 1: 2. Crystalline Form A according to claim 1 in substantially pure form. 3. Crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 6.6±0.2, 7.6±0.2, 9.6±0.2, 12.4±0.2, 13.1±0.2, 15.2±0.2, 16.4±0.2, 18.2±0.2, and 18.6±0.2. 4. Crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 6.6±0.2, 9.6±0.2, 13.1±0.2, 15.2±0.2, 18.2±0.2, and 18.6±0.2. 5. Crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram having a signal at three two-theta values of 6.6±0.2, 13.1±0.2, 18.2±0.2. 6. Crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram having a signal at six two-theta values of 6.6±0.2, 9.6±0.2, 13.1±0.2, 15.2±0.2, 18.2±0.2, and 18.6±0.2. 7. Crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram substantially similar to that in FIG. 2 . 8. A pharmaceutical formulation comprising at least one crystalline form according to claim 1 and a pharmaceutically acceptable carrier.

Assignees

Vertex Pharma

Inventors

Classifications

C07D401/14Primary
containing three or more hetero rings · CPC title
C07D231/20
One oxygen atom attached in position 3 or 5 · CPC title
A61P11/00
Drugs for disorders of the respiratory system · CPC title
C07D498/14
Ortho-condensed systems · CPC title
C07D401/04
directly linked by a ring-member-to-ring-member bond · CPC title

Patent family

Related publications grouped by family.

View patent family 60953944

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11453655B2 cover?: Compounds of Formula (I):pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates…
Who is the assignee on this patent?: Vertex Pharma
What technology area does this patent fall under?: Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?: Publication date Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).